<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02450058</url>
  </required_header>
  <id_info>
    <org_study_id>OMI96.018</org_study_id>
    <nct_id>NCT02450058</nct_id>
  </id_info>
  <brief_title>Adjuvant FEC Versus EP in Breast Cancer (MIG5)</brief_title>
  <acronym>MIG5</acronym>
  <official_title>Fluorouracil, Epirubicin and Cyclophosphamide Versus Concurrent Epirubicin and Paclitaxel in Node Positive Early Breast Cancer Patients: a Randomized, Phase III Trial of Gruppo Oncologico Nord-Ovest - Mammella Intergruppo Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</source>
  <brief_summary>
    <textblock>
      In this multicenter, randomized phase III trial, node positive early breast cancer patients
      are randomly assigned to receive either 6 cycles of FEC (5-fluorouracil 600 mg/m2, epirubicin
      60 mg/m2 and cyclophosphamide 600 mg/m2, on day 1, every three weeks) or 4 cycles of EP
      (epirubicin 90 mg/m2 and paclitaxel 175 mg/m2, on day 1, every three weeks). The primary
      study endpoint is overall survival (OS). Secondary endpoints include toxicity and event free
      survival (EFS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the time the Gruppo Oncologico Nord-Ovest- Mammella Intergruppo trial 5 (GONO-MIG5) was
      designed in 1996, paclitaxel was known to have efficacy in patients with advanced breast
      cancer, but its role was still to be established in the adjuvant setting. Therefore the
      GONO-MIG5 trial was designed to compare a standard anthracycline-containing chemotherapy
      regimen, i.e. 5fluorouracil, epirubicin, ciclophosphamide (FEC), given for 6 cycles to a new
      regimen containing both epirubicin and paclitaxel (EP), given concurrently, for 4 cycles.
      This latter regimen was chosen on the basis of the results obtained in metastatic breast
      cancer patients, where the combination of doxorubicin and paclitaxel was associated with more
      than 90% of objective response . Only four cycles of the new regimen were planned since the
      expected toxicity, particularly the cardiotoxicity, was high, and a short treatment duration
      was hoped to be the best strategy to obtain a favourable balance between the toxicity and the
      expected high efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1996</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>within 11 years since the enrolment of the 1st patient</time_frame>
    <description>estimated from the date of randomization to the date of death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>event free survival</measure>
    <time_frame>within 11 years since the enrolment of the 1st patient</time_frame>
    <description>from the date of randomization to the date of local recurrence, distant metastases, second primary cancer, or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity as measured according to the World Health Organization Criteria</measure>
    <time_frame>within the first 30 days after the end of chemotherapy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1055</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Chemotherapy, Adjuvant</condition>
  <arm_group>
    <arm_group_label>FEC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5-Fluorouracil 600 mg/m2, epirubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, intravenously on day 1, every 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epirubicin 90 mg/m2 and paclitaxel 175 mg/m2, 3-hour infusion on day 1, every 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
    <description>600 mg/m2 intravenously on day 1, every 21 days for six cycles</description>
    <arm_group_label>FEC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin</intervention_name>
    <description>60 mg/m2 intravenously on day 1, every 21 days for six cyles</description>
    <arm_group_label>FEC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>600 mg/m2, intravenously on day 1, every 21 days for six cycles</description>
    <arm_group_label>FEC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin</intervention_name>
    <description>90 mg/m2 on day 1, every 21 days for four cycles</description>
    <arm_group_label>EP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>175 mg/m2, 3-hour infusion on day 1, every 21 days for four cycles</description>
    <arm_group_label>EP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with histologically confirmed breast cancer who had undergone radical mastectomy
             or breast-conserving surgery in addition to full ipsilateral axillary lymph node
             dissection

          -  Lymph node-positive disease with less than 10 involved axillary lymph nodes

          -  Surgery performed not more than 5 weeks before randomization

          -  ECOG performance status 0

          -  Absolute neutrophil count ≥ 2,000/mm³

          -  WBC ≥ 3,000/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  AST and ALT ≤ 1.5 times ULN

          -  Postoperative regional radiotherapy limited to the remaining breast admitted for
             patients who received breast-conserving surgery

          -  Written informed consent

        Exclusion Criteria:

          -  Prior or concurrent ipsilateral or contralateral invasive breast carcinoma within the
             last 10 years

          -  Metastatic disease, including metastasis in the ipsilateral supraclavicular lymph
             nodes

          -  Prior chemotherapy or prior cytotoxic regimens or prior hormonal therapy

          -  Pregnant or nursing

          -  Other serious medical illness requiring medication, uncontrolled infections

          -  Other malignancy except adequately treated, cone-biopsied in situ carcinoma of the
             cervix or basal cell or squamous cell carcinoma of the skin

          -  Recent myocardial infarction, congestive heart failure, or serious arrhythmia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lucia Del Mastro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS San Martino - IST, Istituto Nazionale per la Ricerca sul Cancro, Genoa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Federico Castiglione</name>
      <address>
        <city>Alba</city>
        <zip>12051</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ornella Garrone</name>
      <address>
        <city>Cuneo</city>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucia Del Mastro</name>
      <address>
        <city>Genoa</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Giovanna Cavazzini</name>
      <address>
        <city>Mantova</city>
        <zip>46100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andrea Michelotti</name>
      <address>
        <city>Pisa</city>
        <zip>56100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tiziana Scotto</name>
      <address>
        <city>Sassari</city>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antonio Durando</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saverio Danese</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2015</study_first_submitted>
  <study_first_submitted_qc>May 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2015</study_first_posted>
  <last_update_submitted>May 18, 2015</last_update_submitted>
  <last_update_submitted_qc>May 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</investigator_affiliation>
    <investigator_full_name>Lucia Del Mastro,MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>early breast cancer</keyword>
  <keyword>adjuvant chemotherapy</keyword>
  <keyword>FEC</keyword>
  <keyword>paclitaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

